Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently
- 1 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 37 (4) , 1489-1495
- https://doi.org/10.1097/01.qai.0000138983.45235.02
Abstract
Tenofovir disoproxil fumarate (tenofovir DF), the first nucleotide analogue reverse transcriptase inhibitor approved for the treatment of HIV infection, has been associated with renal dysfunction in isolated cases. We investigated the overall incidence and risk of renal dysfunction in individuals receiving tenofovir DF and compared this with other antiretrovirals. Data from the Chelsea and Westminster cohort were analyzed to reveal HIV-positive individuals with a creatinine value greater than 120 μmol/L at any time, the upper limit of normal used by our reference laboratory. These individuals were classified according to antiretroviral exposure and time exposed. A matched case-control study was performed comparing patients who had received tenofovir DF and subsequently developed a creatinine value greater than 120 μmol/L against controls who had been treated with tenofovir DF and had not experienced a creatinine elevation. Of 4183 HIV-positive patients, 1175 were identified as having a recorded creatinine value >120 μmol/L. Comparison of antiretroviral-naive patients and patients exposed to tenofovir DF- and non-tenofovir DF-containing regimens revealed a lower rate ratio and probability of developing a creatinine value >120 μmol/L in patients exposed to tenofovir DF (rate ratio vs. no antiretrovirals = 0.22, 95% confidence interval [CI]: 0.07-0.69; P < 0.001) with no significant difference between HAART regimens, corrected for duration of exposure. Of the 1058 individuals who were exposed to tenofovir DF, 84 (8%) patients experienced a creatinine value >120 μmol/L subsequent to exposure. An alternative etiology of renal dysfunction was found in 75 (90%) of these individuals. Tenofovir DF is not associated with renal dysfunction more frequently than other antiretroviral drugs, and the occurrence of renal dysfunction in this context is usually attributable to other causes.Keywords
This publication has 24 references indexed in Scilit:
- Tenofovir Disoproxil FumarateClinical Infectious Diseases, 2003
- Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 InfectionAnnals of Internal Medicine, 2003
- Extended Treatment With Tenofovir Disoproxil Fumarate in Treatment-Experienced HIV-1–Infected Patients: Genotypic, Phenotypic, and Rebound AnalysesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infectionClinical Therapeutics, 2002
- Increasing Choices for HIV TherapyNew England Journal of Medicine, 2002
- Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFAIDS, 2002
- New Developments in Anti-HIV ChemotherapyCurrent Medicinal Chemistry, 2001
- Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( R )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected AdultsAntimicrobial Agents and Chemotherapy, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- New Drug Shows Promise in MonkeysScience, 1995